SNTI Valuation
Senti Biosciences Inc
$
3.220
- Overview
- Forecast
- Valuation
SNTI Relative Valuation
SNTI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SNTI is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for SNTI's competitors is 10.83, providing a benchmark for relative valuation. Senti Biosciences Inc Corp (SNTI) exhibits a P/S ratio of 16.38, which is 51.18% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
AMZN
Amazon.com Inc
203.370
USD
-1.35%
TSLA
Tesla Inc
347.350
USD
+1.54%
AVGO
Broadcom Inc
229.590
USD
-0.45%
NVDA
NVIDIA Corp
133.760
USD
-1.34%
WMT
Walmart Inc
97.800
USD
-0.33%
AAPL
Apple Inc
207.140
USD
-0.79%
XOM
Exxon Mobil Corp
105.600
USD
-0.82%
META
Meta Platforms Inc
636.910
USD
-0.55%
ORCL
Oracle Corp
159.780
USD
+0.09%
MSFT
Microsoft Corp
455.895
USD
-0.65%
FAQ
Is Senti Biosciences Inc (SNTI) currently overvalued or undervalued?
Senti Biosciences Inc (SNTI) is now in the Overvalued zone, suggesting that its current forward PS ratio of 16.38 is considered Overvalued compared with the five-year average of 13.87. The fair price of Senti Biosciences Inc (SNTI) is between 0.57 to 2.44 according to relative valuation methord. Compared to the current price of 3.22 USD , Senti Biosciences Inc is Overvalued By 31.70% .
What is Senti Biosciences Inc (SNTI) fair value?
How does SNTI's valuation metrics compare to the industry average?
What is the current P/B ratio for Senti Biosciences Inc (SNTI) as of May 20 2025?
What is the current FCF Yield for Senti Biosciences Inc (SNTI) as of May 20 2025?
What is the current Forward P/E ratio for Senti Biosciences Inc (SNTI) as of May 20 2025?